Posts Tagged With 'hyperkalemia'

Posted by TwillyD July 23, 2016

Relypsa Just Made a Move That Could Give AstraZeneca Pause

Last month we told you about Relypsa (NASDAQ: RLYP) a biopharmaceutical company that was enjoying being the sole provider of a drug used to treat hyperkalemia, a condition that causes life-threatening levels of potassium in a person’s blood. At the time we first reported Relypsa, we noted that the company’s stock was up and had Continue reading →

Posted by TwillyD June 07, 2016

Relypsa’s Drug Treatment Success Threatened By Looming New Player Entranceent as Big Pharma

Biopharmaceutical company Relypsa Inc. (NASDAQ: RLYP) continues to enjoy being the sole provider of a drug used to treat hyperkalemia. Its stock is up and analysts are bullish that it has more room to run. However, there are some catalysts that could move the stock downward. Because of some issues that could affect shareholder value, Continue reading →